Phase 1 dose escalation study evaluating the safety and tolerability of pf-06804103 in patients with human epidermal growth factor receptor 2 (her2) positive solid tumors
2017-002538-22Tumores sólidos con HER2 positivoFundación Jiménez DíazInvestigador: Moreno Garcia Victor